Stem definition | Drug id | CAS RN |
---|---|---|
opioid receptor agonists, analgesics, fentanyl derivatives | 114 | 71195-58-9 |
None
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 1 | Benet LZ, Broccatelli F, Oprea TI |
EoM (Fraction excreted unchanged in urine) | 0.50 % | Benet LZ, Broccatelli F, Oprea TI |
MRTD (Maximum Recommended Therapeutic Daily Dose) | 0.59 ยตM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
BA (Bioavailability) | 1 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Vd (Volume of distribution) | 0.45 L/kg | Lombardo F, Berellini G, Obach RS |
CL (Clearance) | 3.90 mL/min/kg | Lombardo F, Berellini G, Obach RS |
fu (Fraction unbound in plasma) | 0.09 % | Lombardo F, Berellini G, Obach RS |
t_half (Half-life) | 1.60 hours | Lombardo F, Berellini G, Obach RS |
Date | Agency | Company | Orphan |
---|---|---|---|
Dec. 29, 1986 | FDA | AKORN |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Epilepsy with myoclonic-atonic seizures | 62.27 | 58.10 | 8 | 685 | 105 | 63488224 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Toxic epidermal necrolysis | 113.57 | 47.47 | 34 | 708 | 21612 | 34934577 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Toxic epidermal necrolysis | 96.90 | 40.32 | 35 | 1462 | 44546 | 79698345 |
Anaphylactic shock | 80.96 | 40.32 | 29 | 1468 | 35967 | 79706924 |
Epilepsy with myoclonic-atonic seizures | 57.70 | 40.32 | 8 | 1489 | 108 | 79742783 |
Anaphylactic reaction | 48.72 | 40.32 | 26 | 1471 | 83717 | 79659174 |
Change in seizure presentation | 45.67 | 40.32 | 8 | 1489 | 514 | 79742377 |
None
Source | Code | Description |
---|---|---|
ATC | N01AH02 | NERVOUS SYSTEM ANESTHETICS ANESTHETICS, GENERAL Opioid anesthetics |
CHEBI has role | CHEBI:35482 | narcotic analgesic |
CHEBI has role | CHEBI:35488 | central nervous system depressants |
CHEBI has role | CHEBI:38877 | intravenous anesthetics |
CHEBI has role | CHEBI:49110 | peripheral nervous system drugs |
CHEBI has role | CHEBI:55322 | mu-opioid agonists |
FDA MoA | N0000175684 | Full Opioid Agonists |
FDA EPC | N0000175690 | Opioid Agonist |
MeSH PA | D000700 | Analgesics |
MeSH PA | D000701 | Analgesics, Opioid |
MeSH PA | D000777 | Anesthetics |
MeSH PA | D018686 | Anesthetics, Intravenous |
MeSH PA | D002491 | Central Nervous System Agents |
MeSH PA | D002492 | Central Nervous System Depressants |
MeSH PA | D009294 | Narcotics |
MeSH PA | D018373 | Peripheral Nervous System Agents |
MeSH PA | D018689 | Sensory System Agents |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
General anesthesia | indication | 50697003 | |
Pain | off-label use | 22253000 | |
Sedation in Intubated Patients | off-label use | ||
Asthenia | contraindication | 13791008 | |
Chronic disease of respiratory system | contraindication | 17097001 | |
Low blood pressure | contraindication | 45007003 | |
Bradycardia | contraindication | 48867003 | |
Benign intracranial hypertension | contraindication | 68267002 | DOID:11459 |
Injury of head | contraindication | 82271004 | |
Kidney disease | contraindication | 90708001 | DOID:557 |
Disease of liver | contraindication | 235856003 | DOID:409 |
Lesion of brain | contraindication | 301766008 |
None
None
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 6.71 | Basic |
pKa2 | 0.12 | Basic |
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Mu-type opioid receptor | GPCR | AGONIST | EC50 | 8.50 | WOMBAT-PK | CHEMBL | |||
Multidrug resistance protein 1 | Transporter | IC50 | 3.95 | WOMBAT-PK | |||||
Mu-type opioid receptor | GPCR | Ki | 8.09 | CHEMBL | |||||
Mu-type opioid receptor | GPCR | IC50 | 7.82 | CHEMBL | |||||
Opioid receptor | GPCR | Ki | 8.09 | CHEMBL |
ID | Source |
---|---|
4019597 | VUID |
N0000147693 | NUI |
D00835 | KEGG_DRUG |
70879-28-6 | SECONDARY_CAS_RN |
203203 | RXNORM |
C0002026 | UMLSCUI |
CHEBI:2569 | CHEBI |
CHEMBL634 | ChEMBL_ID |
CHEMBL1200531 | ChEMBL_ID |
D015760 | MESH_DESCRIPTOR_UI |
DB00802 | DRUGBANK_ID |
51263 | PUBCHEM_CID |
7108 | IUPHAR_LIGAND_ID |
4818 | INN_ID |
1N74HM2BS7 | UNII |
387560008 | SNOMEDCT_US |
96183007 | SNOMEDCT_US |
96184001 | SNOMEDCT_US |
4019322 | VANDF |
4019597 | VANDF |
1670 | MMSL |
41329 | MMSL |
4147 | MMSL |
d00167 | MMSL |
001571 | NDDF |
004631 | NDDF |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Alfentanil Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 17478-067 | INJECTION | 500 ug | INTRAVENOUS | NDA | 27 sections |
Alfentanil Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 17478-067 | INJECTION | 500 ug | INTRAVENOUS | NDA | 27 sections |
Alfentanil Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 17478-067 | INJECTION | 500 ug | INTRAVENOUS | NDA | 27 sections |
Alfentanil | HUMAN PRESCRIPTION DRUG LABEL | 1 | 17478-841 | INJECTION | 500 ug | INTRAVENOUS | NDA | 22 sections |